Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009;9(15):1479-92.
doi: 10.2174/156802609789895728.

Update on Hsp90 inhibitors in clinical trial

Y S Kim  1 , S V Alarcon, S Lee, M-J Lee, G Giaccone, L Neckers, J B Trepel
Affiliations
Review

Update on Hsp90 inhibitors in clinical trial

Y S Kim et al. Curr Top Med Chem. 2009.

Abstract

Twenty-five years ago the first small molecule inhibitors of Hsp90 were identified. In the intervening years there has been dramatic progress in basic scientific understanding of the Hsp90 chaperone machinery and in the role of Hsp90 in malignancy. The first-in-class Hsp90 inhibitor 17-AAG entered into Phase I clinical trials in 1999. There are now 13 Hsp90 inhibitors in clinical trial, representing multiple drug classes, and hundreds of patients have been treated in adult oncology and pediatric oncology trials. This review will provide an overview of the clinical trial results thus far. In addition, pivotal issues in further development of Hsp90 inhibitors as anticancer drugs will be discussed.

PubMed Disclaimer

References

    1. Uehara Y Natural product origins of Hsp90 inhibitors. Curr. Cancer Drug Targets, 2003, 3, 325–330. - PubMed
    1. Uehara Y; Hori M; Takeuchi T; Umezawa H Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol. Cell. Biol, 1986, 6, 2198–2206. - PMC - PubMed
    1. Whitesell L; Mimnaugh EG; De Costa B; Myers CE; Neckers LM Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA, 1994, 91, 8324–8328. - PMC - PubMed
    1. Banerji U Heat shock protein 90 as a drug target: some like it hot. Clin. Cancer Res, 2009, 15, 9–14. - PubMed
    1. Erlichman C Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin. Investig. Drugs, 2009, 18, 861–868. - PubMed

MeSH terms

Substances